Cambrex Corp.

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Evonik is discontinuing keto acid manufacturing at its site in Hanau, Germany, by the end of 2025 and will lay off around 260 workers. The company is also looking at divestment and partnership options for its keto and pharma amino acid facilities in France and China, according to an Oct. 11 release. Italian biopharma Chiesi is launching a new €400 million ($433 million) facility in Europe to make monoclonal antibodies, enzymes and other proteins, the company said Monday. The new site will employ 200 staffers by the end of 2025. Indiana-headquartered SpectronRx is expanding to Europe with the radiopharma CDMO earmarking $50 million to build a radiolabeling facility for actinium-225 assets, the company told Endpoints Thursday. Construction in Mol, Belgium, is anticipated to be completed next month, with the site to be operational by the first quarter of 2025. EuroAPI has appointed Olivier Falut as its new chief financial officer. He is replacing Evelyne Nguyen who will stay at the company until the end of October, according to a Wednesday release. The company is in its “year of transition” as it undergoes major restructuring. Texas-based CDMO Matica Biotechnology has signed a new contract with biotech Mongoose Bio, the companies announced Wednesday . Matica Bio will manufacture lentiviruses for Mongoose Bio’s T cell receptor-engineered T cell therapy for cancer. RadioPharma CDMO AtomVie has partnered with Radiopharm Ventures, the company said Tuesday. AtomVie will manufacture the clinical-stage 177 lutetium-conjugated B7-H3-targeting radio antibody, dubbed 177Lu-BetaBart. Perspective Therapeutics’ manufacturing facility in Somerset, NJ, is now operational and has sent its first shipment, the company said Wednesday. The facility manufactures lead-203 and lead-212-labeled radiopharmaceuticals. Cellular Origins and Fresenius Kabi have embarked on a new collaboration for cell therapy manufacturing, the companies announced Wednesday. Cellular Origins will integrate Fresenius Kabi’s cell therapy processing tech into its robotic manufacturing platform, with the aim to manufacture cell therapies on a larger scale. CDMO Cambrex’s storage subsidiary Q1 Scientific has opened a new facility in Durham, NC, to expand storage capacity for pharmaceutical, medical device and life science customers in North America, Cambrex said Wednesday.

EAST RUTHERFORD, N.J., Sept. 19, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, obviating the dependency on specialized, solid-phase reactors. This new LPPS technology materially reduces solvent demand and the need for excess reagents compared to standard solid-state peptide synthesis processes. Continue Reading Snapdragon Chemistry Logo "Over the past several years, we have made significant investments in the research and development of complex synthetics, specifically to reduce the economic and environmental impacts of manufacturing peptides and oligonucleotides," said Dr. Matt Bio, Chief Scientific Officer, Cambrex. "Our new LPPS technology provides a significantly more cost-efficient and environmentally sustainable solution when compared to traditional solid-phase peptide synthesis, substantially reducing solvent usage and allowing the substitution of sustainable solvents." The LPPS technology supports peptides up to 12 residues long, while larger peptides are then assembled in liquid phase, using a convergent fragment coupling approach. Processes developed with Cambrex's LPPS technology can be scaled in the same way as traditional small molecules. In addition to the LPPS, Cambrex also developed unique capabilities in peptide and protein crystallization, including a crystallization screening platform specifically for the discovery of crystalline forms of peptides and proteins. Crystallization can deliver improved product quality and stability and reduce the need for time-consuming preparative chromatography and lyophilization. "With the clinical and commercial successes of peptide-based therapies, it's imperative that we provide industry-leading solutions to develop and scale peptide candidates," said Thomas Loewald, CEO at Cambrex. Cambrex will continue to invest in R&D across complex synthetic modalities, including further technology development for peptides, as well as new research on the application of artificial intelligence for the optimization of oligonucleotide processes. About Snapdragon Chemistry Snapdragon Chemistry, a Cambrex company, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon's 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff. About Cambrex Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services. With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs. Logo : Logo : SOURCE Cambrex WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Beshar as Independent Chair of its Board of Directors. He succeeds Martin Murphy, Quell’s founding Chair. Luke is a seasoned biopharmaceutical leader with a proven track record of more than 35 years of strategic development, financial and transactional experience from his Board and C-suite executive roles at several innovative, high-growth public and private companies. He currently serves as Chair of Protara Therapeutics, Inc., a US Nasdaq-listed immune-oncology company and Chair of Inotrem S.A., an advanced clinical-stage company developing targeted immunotherapies for acute and chronic inflammatory syndromes. Previously Luke served as Non-executive Director (NED) and Chair of the Audit Committee of Omega Therapeutics, Inc., a US Nasdaq-listed company pioneering a new class of DNA-sequence-targeting mRNA-encoded therapeutics, a NED and Chair of the Compensation and Audit Committees at immune-oncology company Trillium Therapeutics, Inc., from 2014 until it was acquired by Pfizer in 2021, and NED and Chair of the Audit Committee at gene therapy company REGENXBIO, Inc., from 2015 (pre-IPO) to 2021. Prior to this, Luke was Executive Vice President (EVP) and Chief Financial Officer (CFO) of NPS Pharmaceuticals, Inc. from November 2007 until it was acquired by Shire plc (now part of Takeda) in 2015, and EVP and CFO of Cambrex Corporation, from 2002 to 2007. Iain McGill, CEO of Quell, said: “We are thrilled to welcome Luke to our Board at this important time for Quell, as we advance the LIBERATE Phase 1/2 trial with QEL-001, a potentially transformational therapy for liver transplant patients, and further explore the potential of multi-modular CAR-Treg cell therapy in major immune disorders. Luke’s extensive experience and expertise in the biopharma industry will be crucial as we execute our strategy to build a truly world-class company.” Luke Beshar added: “Quell is making huge strides pioneering a new paradigm in cell therapy for immune-related disorders; one that has the potential to make a significant and highly positive impact on patients’ lives. I am honored to join the Company at such an exciting time and look forward to working with the Board and talented team to help deliver on the huge potential of Treg cell therapy.” Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University, is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia and is a Certified Public Accountant. About Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system. The Company is leveraging its pioneering Foxp3 Phenotype Lock™ technology, unique multi-modular platform and integrated manufacturing capabilities to design and develop a pipeline of highly engineered Treg cell therapies with greater potential for persistence, potency and stability than earlier generations of Treg cell therapy approaches. Quell’s lead candidate QEL-001 is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications. Quell is also advancing additional programs in neuroinflammatory and autoimmune diseases internally and in partnership with AstraZeneca. www.quell-tx.com. Contacts Luke Henry, Chief Business Officer Quell Therapeutics IR@quell-tx.com Media: Mark Swallow, Frazer Hall, Sandi Greenwood MEDiSTRAVA Quell-Tx@Medistrava.com Investors: Corey Davis, PhD LifeSci Advisors cdavis@lifesciadvisors.com